Biogen Inc. management reported progress across its portfolio, showing unexpectedly strong growth in Avonex (interferon beta-1a), flat sales from Tysabri (natalizumab), and an incipient but growing share from Fampyra (prolonged-release fampridine tablets), the treatment for walking impairment in multiple sclerosis patients for which Biogen licensed ex-US rights from Acorda Therapeutics Inc.[See Deal].
In a sign of the new commercial landscape with which companies must now contend, European austerity, drug sale tenders in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?